It induces an inflammasome signaling cascade in response to anti-PD-1 therapy, resulting in the recruitment of granulocytic myeloid-derived suppressor cells (MDSCs), immune cells known for their ability to suppress immune response, to the tumor site and the decreased efficacy of anti-PD-1 therapy [290]. Here, PDCD1 is linked to neoplasm.